CMV infections after discontinuation of LET prophylaxis
| Patient no. . | Day of LET dc . | Any viremia after LET dc (day of onset after ET dc) . | Late csCMVi . | Initial (peak) viremia after LET dc, IU/mL . | No. of days to valganciclovir initiation after LET dc . | Comments . |
|---|---|---|---|---|---|---|
| Letermovir discontinuation before day 180 | ||||||
| 1 | 119 | Yes 18 | No | <137 (<137) | – | Spontaneous resolution |
| 2 | 145 | Yes 41 | No | <137 (266) | – | Leukemia relapse day 172. CMV reactivation day 186 -> LET restarted day 193 -> viremia resolution -> LET continued until death |
| 3 | 169 | No | No | – | – | |
| Letermovir discontinuation after day 180 without CMV viremia | ||||||
| 4 | 211 | No | No | – | – | |
| 5 | 278 | No | No | – | – | 18-d interruption (days 116-134) due to insurance denial with a single episode of CMV viremia (<137 IU/mL). No subsequent viremia after LET dc |
| 6 | 383 | No | No | – | – | |
| 7 | 446 | No | No | – | – | |
| Letermovir discontinuation after day 180 with CMV reactivation without csCMVi | ||||||
| 8 | 231 | Yes 67 | No | <137 (<137) | – | Spontaneous resolution |
| 9 | 273 | Yes 70 | No | <137 (<137) | – | Spontaneous resolution |
| 10 | 340 | Yes 29 | No | 251 (324) | – | Spontaneous resolution |
| 11 | 368 | Yes 140 | No | <137 (<137) | – | Spontaneous resolution |
| 12 | 372 | Yes 42 | No | <137 (<137) | – | Spontaneous resolution |
| 13 | 401 | Yes 70 | No | <137 (<137) | – | Spontaneous resolution |
| 14 | 414 | Yes 21 | No | <137 (<137) | – | Spontaneous resolution |
| 15 | 419 | Yes 55 | No | <137 (<137) | – | Spontaneous resolution |
| Letermovir discontinuation after day 180 with csCMVi | ||||||
| 16 | 222 | Yes 7 | Yes | <137 (1806) | 30 | Valganciclovir (12-d) -> viremia resolution -> secondary LET prophylaxis (days 264-399). After secondary LET dc: transient viremia (<137 IU/mL), no csCMVi |
| 17 | 254 | Yes 24 | Yes | <137 (649) | 33 | Valganciclovir (58-d) -> viremia resolution. No subsequent csCMVi |
| 18 | 398 | Yes 29 | Yes | <137 (877) | 43 | Valganciclovir (38 d) -> viremia resolution. No subsequent csCMVi |
| 19 | 402 | Yes 18 | Yes | <137 (347) | 25 | Valganciclovir (67 d total): valganciclovir (39 d) -> initial viremia resolution -> second csCMVi (peak viral load 216 IU/mL) -> valganciclovir (28 d) -> viremia resolution. No subsequent csCMVi |
| 20 | 455 | Yes 30 | Yes | <137 (1095) | 44 | Valganciclovir (63 d) -> viremia resolution. No subsequent csCMVi |
| Patient no. . | Day of LET dc . | Any viremia after LET dc (day of onset after ET dc) . | Late csCMVi . | Initial (peak) viremia after LET dc, IU/mL . | No. of days to valganciclovir initiation after LET dc . | Comments . |
|---|---|---|---|---|---|---|
| Letermovir discontinuation before day 180 | ||||||
| 1 | 119 | Yes 18 | No | <137 (<137) | – | Spontaneous resolution |
| 2 | 145 | Yes 41 | No | <137 (266) | – | Leukemia relapse day 172. CMV reactivation day 186 -> LET restarted day 193 -> viremia resolution -> LET continued until death |
| 3 | 169 | No | No | – | – | |
| Letermovir discontinuation after day 180 without CMV viremia | ||||||
| 4 | 211 | No | No | – | – | |
| 5 | 278 | No | No | – | – | 18-d interruption (days 116-134) due to insurance denial with a single episode of CMV viremia (<137 IU/mL). No subsequent viremia after LET dc |
| 6 | 383 | No | No | – | – | |
| 7 | 446 | No | No | – | – | |
| Letermovir discontinuation after day 180 with CMV reactivation without csCMVi | ||||||
| 8 | 231 | Yes 67 | No | <137 (<137) | – | Spontaneous resolution |
| 9 | 273 | Yes 70 | No | <137 (<137) | – | Spontaneous resolution |
| 10 | 340 | Yes 29 | No | 251 (324) | – | Spontaneous resolution |
| 11 | 368 | Yes 140 | No | <137 (<137) | – | Spontaneous resolution |
| 12 | 372 | Yes 42 | No | <137 (<137) | – | Spontaneous resolution |
| 13 | 401 | Yes 70 | No | <137 (<137) | – | Spontaneous resolution |
| 14 | 414 | Yes 21 | No | <137 (<137) | – | Spontaneous resolution |
| 15 | 419 | Yes 55 | No | <137 (<137) | – | Spontaneous resolution |
| Letermovir discontinuation after day 180 with csCMVi | ||||||
| 16 | 222 | Yes 7 | Yes | <137 (1806) | 30 | Valganciclovir (12-d) -> viremia resolution -> secondary LET prophylaxis (days 264-399). After secondary LET dc: transient viremia (<137 IU/mL), no csCMVi |
| 17 | 254 | Yes 24 | Yes | <137 (649) | 33 | Valganciclovir (58-d) -> viremia resolution. No subsequent csCMVi |
| 18 | 398 | Yes 29 | Yes | <137 (877) | 43 | Valganciclovir (38 d) -> viremia resolution. No subsequent csCMVi |
| 19 | 402 | Yes 18 | Yes | <137 (347) | 25 | Valganciclovir (67 d total): valganciclovir (39 d) -> initial viremia resolution -> second csCMVi (peak viral load 216 IU/mL) -> valganciclovir (28 d) -> viremia resolution. No subsequent csCMVi |
| 20 | 455 | Yes 30 | Yes | <137 (1095) | 44 | Valganciclovir (63 d) -> viremia resolution. No subsequent csCMVi |
dc, discontinuation; LET, letermovir.